Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

Inclusion Criteria: * Male or female patient fully capable of informed consent * Informed consent * Age 18-80 years (both years inclusive) * T2DM diagnosed at least 3 months prior to visit 0 * NYHA class I-III at visit 0 * E/e\* ≥ 9 or e\* (lateral) ≤10 cm/sec, or both * LVEF \> 50% * LVEDV/BSA \< 97 ml/m2 * Stable on heart medication for 6 weeks prior to randomisation * Stable on antidiabetic treatment for 30 days prior to randomisation * T2DM must be either treated with one or more oral anti-diabetic drugs or treated with human NPH-insulin or long-acting insulin analogue, alone or in combination with oral drugs Exclusion Criteria: * Lack of consent. * NYHA class IV * Type 1 diabetes mellitus * Incretin-based therapy (GLP-1 receptor agonists; exenatide, liraglutide or other and DPP-IV inhibitors) within 30 days prior to randomisation (visit 1) * Glitazon therapy within 30 days prior to randomisation (visit 1) * Hypertension with inadequate blood pressure control: Systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \>85 mmHg\* * Supine systolic blood pressure \<85 mmHg measured at visit 0 * Significant valvular heart disease * Hypertrophic cardiomyopathy, ARVC/D, non-compaction or amyloidosis * Myocardial infarction, unstable angina, angina on exertion (≥CCS class 2) or coronary revascularization within 3 months prior to randomisation (visit 1) * Hospitalisation due to incompensated heart disease within 30 days to randomisation (visit 1) * HbA1c \>10% at visit 0 * eGFR\< 60 ml/min/1,73 m2 at visit 0 * Liver disease with aspartate aminotransferase/alanine aminotransferase \>3 times upper limit of normal measured at visit 0\*\* * Hypokalaemia (P-potassium \<3.5 mmol/L) or hyperkalaemia (P-potassium \>5.5 mmol/L) measured at visit 0\*\* * Anaemia (haemoglobin \<6.5 mmol/L) measured at visit 0\*\* * Conditions that may be associated with changes in markers of fibroses or collagen turnover (eg. on-going or active rheumatological disease requiring anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer) * Prolonged use (\> 2 weeks) of glucocorticoids or NSAIDs within 2 weeks prior to visit 0 * Women of childbearing potential who are not on acceptable contraception. See below. * Pregnant or breastfeeding women * Cancer (except basal cell skin cancer or squamous cell skin cancer) unless complete remission for ≥ 5 years * Alcohol/drug abuse * Chronic or previous acute pancreatitis * History of thyroid adenoma or carcinoma * Inflammatory bowel disease * Clinical signs of diabetic gastroparesis * ICD/pacemaker or other contraindications to MRI scan * Severe claustrophobia * Atrial fibrillation * Contraindications to glycopyrrolate: closed-angle glaucoma, prostate hyperplasia, tachycardia, bladder atony, cardia insufficiency, non-congenital pylorus stenosis and gastroparesis * Known or suspected hypersensitivity to trial product or related products * Current participation in any other clinical intervention trial * Receipt of an investigational drug with 30 days prior to visit 0 * Other concominant disease or treatment that according to investigator's assessment makes the patient unsuitable for participation in the study * Measured twice at visit 0. In case of elevation, an ambulatory (24-hour) blood pressure will be performed, and the result of this will be conclusive * Measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value will be conclusive.